Clin2
NCT06223542Possibly a fitRecruiting

TAK-243 for advanced cancers that haven't responded to other treatments

Advanced LymphomaAdvanced Malignant Solid NeoplasmIndolent Non-Hodgkin LymphomaMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm

Part of Cancer clinical trials.

This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
95 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have advanced cancer (solid tumor or lymphoma) that has gotten worse or not responded to other treatments.
  • Your cancer can be seen on scans or measured (like a tumor).
  • It has been at least 4 weeks since your last cancer treatment (or 2 weeks for palliative radiation).
  • Your blood cell counts, kidney function, and liver function are within safe limits (based on blood tests).
  • You do not have serious heart or lung problems, or certain other medical conditions.
  • You are willing to use effective birth control during and for 4 months after treatment, if applicable.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06911008Recruiting· Phase 1
Testing a new drug for advanced solid cancers

This trial tests a new drug (MTI-301) for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and shrinks tumors.

Jacksonville, Florida
NCT07205718Recruiting· Phase 1/Phase 2
TAK-188 for advanced solid tumors after immunotherapy

This trial tests a new medication called TAK-188 for people with certain advanced solid tumors that have not responded to standard therapies, including checkpoint inhibitors. It aims to see if TAK-188 can help shrink or control the cancer.

Santa Monica, California
NCT07436728Recruiting· Phase 1/Phase 2
Study of TAK-505 for adults with solid tumors

This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.

Orange, California
NCT07391644Not yet recruiting· Phase 1
Testing JSKN027 for advanced solid tumors that have progressed

This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.

Beijing, Beijing Municipality
NCT06682780Recruiting· Phase 1/Phase 2
Testing LM-2417 for advanced solid tumors

This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.

Shanghai, Shanghai Municipality
NCT06386705Recruiting· Phase 1
Testing TSN084 for advanced cancers

This trial tests an experimental drug called TSN084 for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.

Beijing, Beijing Municipality

Hear when a new Advanced Lymphoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.